-
1
-
-
0033946560
-
Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy)
-
Andersson B.S., Gajewski J., Donato M., et al. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant 25 Suppl 2 (2000) S35-S38
-
(2000)
Bone Marrow Transplant
, vol.25
, Issue.SUPPL. 2
-
-
Andersson, B.S.1
Gajewski, J.2
Donato, M.3
-
2
-
-
0742323838
-
Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit
-
Andersson B.S., Kashyap A., Couriel D., et al. Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. Biol Blood Marrow Transplant 9 (2003) 722-724
-
(2003)
Biol Blood Marrow Transplant
, vol.9
, pp. 722-724
-
-
Andersson, B.S.1
Kashyap, A.2
Couriel, D.3
-
3
-
-
0036205591
-
Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study
-
Andersson B.S., Kashyap A., Gian V., et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 8 (2002) 145-154
-
(2002)
Biol Blood Marrow Transplant
, vol.8
, pp. 145-154
-
-
Andersson, B.S.1
Kashyap, A.2
Gian, V.3
-
4
-
-
0034567061
-
Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study
-
Andersson B.S., Madden T., Tran H.T., et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 6 (2000) 548-554
-
(2000)
Biol Blood Marrow Transplant
, vol.6
, pp. 548-554
-
-
Andersson, B.S.1
Madden, T.2
Tran, H.T.3
-
5
-
-
0036398471
-
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia
-
Andersson B.S., Thall P.F., Madden T., et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 8 (2002) 477-485
-
(2002)
Biol Blood Marrow Transplant
, vol.8
, pp. 477-485
-
-
Andersson, B.S.1
Thall, P.F.2
Madden, T.3
-
6
-
-
3242810563
-
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
-
de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104 (2004) 857-864
-
(2004)
Blood
, vol.104
, pp. 857-864
-
-
de Lima, M.1
Couriel, D.2
Thall, P.F.3
-
7
-
-
0036400369
-
Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality
-
Kashyap A., Wingard J., Cagnoni P., et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 8 (2002) 493-500
-
(2002)
Biol Blood Marrow Transplant
, vol.8
, pp. 493-500
-
-
Kashyap, A.1
Wingard, J.2
Cagnoni, P.3
-
8
-
-
0036401558
-
Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes
-
Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 8 (2002) 468-476
-
(2002)
Biol Blood Marrow Transplant
, vol.8
, pp. 468-476
-
-
Russell, J.A.1
Tran, H.T.2
Quinlan, D.3
-
9
-
-
3242709629
-
Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: bayesian sensitivity analyses of confounded treatment and center effects
-
Thall P.F., Champlin R.E., and Andersson B.S. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant 33 (2004) 1191-1199
-
(2004)
Bone Marrow Transplant
, vol.33
, pp. 1191-1199
-
-
Thall, P.F.1
Champlin, R.E.2
Andersson, B.S.3
-
10
-
-
37349060017
-
Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation
-
Bartelink I.H., Bredius R.G., Ververs T.T., et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 14 (2008) 88-98
-
(2008)
Biol Blood Marrow Transplant
, vol.14
, pp. 88-98
-
-
Bartelink, I.H.1
Bredius, R.G.2
Ververs, T.T.3
-
11
-
-
33745449021
-
Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation
-
Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 12 (2006) 560-565
-
(2006)
Biol Blood Marrow Transplant
, vol.12
, pp. 560-565
-
-
Bacigalupo, A.1
Lamparelli, T.2
Barisione, G.3
-
12
-
-
33745470309
-
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen
-
Deeg H.J., Storer B.E., Boeckh M., et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 12 (2006) 573-584
-
(2006)
Biol Blood Marrow Transplant
, vol.12
, pp. 573-584
-
-
Deeg, H.J.1
Storer, B.E.2
Boeckh, M.3
-
13
-
-
0036861875
-
Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis
-
Duggan P., Booth K., Chaudhry A., et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 30 (2002) 681-686
-
(2002)
Bone Marrow Transplant
, vol.30
, pp. 681-686
-
-
Duggan, P.1
Booth, K.2
Chaudhry, A.3
-
14
-
-
33847046703
-
Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis
-
Russell J.A., Turner A.R., Larratt L., et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant 13 (2007) 299-306
-
(2007)
Biol Blood Marrow Transplant
, vol.13
, pp. 299-306
-
-
Russell, J.A.1
Turner, A.R.2
Larratt, L.3
-
15
-
-
34250173083
-
Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin
-
Russell J.A., Savoie M.L., Balogh A., et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 13 (2007) 814-821
-
(2007)
Biol Blood Marrow Transplant
, vol.13
, pp. 814-821
-
-
Russell, J.A.1
Savoie, M.L.2
Balogh, A.3
-
16
-
-
0033631658
-
Early outcomes after allogeneic stem cell transplantation for leukemia and myelodysplasia without protective isolation: a 10-year experience
-
Russell J.A., Chaudhry A., Booth K., et al. Early outcomes after allogeneic stem cell transplantation for leukemia and myelodysplasia without protective isolation: a 10-year experience. Biol Blood Marrow Transplant 6 (2000) 109-114
-
(2000)
Biol Blood Marrow Transplant
, vol.6
, pp. 109-114
-
-
Russell, J.A.1
Chaudhry, A.2
Booth, K.3
-
17
-
-
0028024639
-
Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease
-
Russell J.A., Woodman R.C., Poon M.C., Jones A.R., and Ruether B.A. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease. Bone Marrow Transplant 14 (1994) 397-401
-
(1994)
Bone Marrow Transplant
, vol.14
, pp. 397-401
-
-
Russell, J.A.1
Woodman, R.C.2
Poon, M.C.3
Jones, A.R.4
Ruether, B.A.5
-
18
-
-
0000899005
-
Graft-versus-host disease
-
Treleaven J., and Barrett J. (Eds), Churchill Livingstone, Edinburgh
-
Barrett J. Graft-versus-host disease. In: Treleaven J., and Barrett J. (Eds). Bone marrow transplantation in practice (1992), Churchill Livingstone, Edinburgh 257
-
(1992)
Bone marrow transplantation in practice
, pp. 257
-
-
Barrett, J.1
-
19
-
-
0023574955
-
Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen
-
Tutschka P.J., Copelan E.A., and Klein J.P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70 (1987) 1382-1388
-
(1987)
Blood
, vol.70
, pp. 1382-1388
-
-
Tutschka, P.J.1
Copelan, E.A.2
Klein, J.P.3
-
20
-
-
0027160828
-
Busulfan and cyclophosphamide versus cyclophosphamide and total body irradiation for marrow transplantation in chronic myelogenous leukemia-a review
-
Santos G.W. Busulfan and cyclophosphamide versus cyclophosphamide and total body irradiation for marrow transplantation in chronic myelogenous leukemia-a review. Leuk Lymphoma 11 Suppl 1 (1993) 201-204
-
(1993)
Leuk Lymphoma
, vol.11
, Issue.SUPPL. 1
, pp. 201-204
-
-
Santos, G.W.1
-
21
-
-
0023552434
-
Venoocclusive disease of the liver following bone marrow transplantation
-
Jones R.J., Lee K.S., Beschorner W.E., et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 44 (1987) 778-783
-
(1987)
Transplantation
, vol.44
, pp. 778-783
-
-
Jones, R.J.1
Lee, K.S.2
Beschorner, W.E.3
-
22
-
-
0027478056
-
Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients
-
McDonald G.B., Hinds M.S., Fisher L.D., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118 (1993) 255-267
-
(1993)
Ann Intern Med
, vol.118
, pp. 255-267
-
-
McDonald, G.B.1
Hinds, M.S.2
Fisher, L.D.3
-
23
-
-
0036204648
-
Cellular and clinical pharmacology of fludarabine
-
Gandhi V., and Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 41 (2002) 93-103
-
(2002)
Clin Pharmacokinet
, vol.41
, pp. 93-103
-
-
Gandhi, V.1
Plunkett, W.2
-
24
-
-
0000656583
-
Myeloablative chemotherapy for allogeneic transplantation with a Fludarabine/Busulfan protocol (FLUBUP): comparison with BUCY
-
(abstr 124)
-
Chaudhry M.A., Duggan P., Brown C.B., et al. Myeloablative chemotherapy for allogeneic transplantation with a Fludarabine/Busulfan protocol (FLUBUP): comparison with BUCY. Biol Blood Marrow Transplant 2 (2000) 140 (abstr 124)
-
(2000)
Biol Blood Marrow Transplant
, vol.2
, pp. 140
-
-
Chaudhry, M.A.1
Duggan, P.2
Brown, C.B.3
-
25
-
-
85112388301
-
Daily intravenous busulfan (BU): comparison with conventional oral BU in combination with fludarabine as conditioning for allogeneic stem cell transplant
-
(abstr 5188)
-
Russell J.A., Chaudhry A.M., Duggan P., et al. Daily intravenous busulfan (BU): comparison with conventional oral BU in combination with fludarabine as conditioning for allogeneic stem cell transplant. Blood 96 (2000) 11 (abstr 5188)
-
(2000)
Blood
, vol.96
, pp. 11
-
-
Russell, J.A.1
Chaudhry, A.M.2
Duggan, P.3
-
26
-
-
0035880789
-
Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis
-
Cutler C., Giri S., Jeyapalan S., Paniagua D., Viswanathan A., and Antin J.H. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 19 (2001) 3685-3691
-
(2001)
J Clin Oncol
, vol.19
, pp. 3685-3691
-
-
Cutler, C.1
Giri, S.2
Jeyapalan, S.3
Paniagua, D.4
Viswanathan, A.5
Antin, J.H.6
-
27
-
-
0029057117
-
Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics
-
Slattery J.T., Sanders J.E., Buckner C.D., et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16 (1995) 31-42
-
(1995)
Bone Marrow Transplant
, vol.16
, pp. 31-42
-
-
Slattery, J.T.1
Sanders, J.E.2
Buckner, C.D.3
-
28
-
-
0034016713
-
An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease
-
Bolinger A.M., Zangwill A.B., Slattery J.T., et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 25 (2000) 925-930
-
(2000)
Bone Marrow Transplant
, vol.25
, pp. 925-930
-
-
Bolinger, A.M.1
Zangwill, A.B.2
Slattery, J.T.3
-
29
-
-
0025121395
-
Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study
-
Vassal G., Deroussent A., Hartmann O., et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 50 (1990) 6203-6207
-
(1990)
Cancer Res
, vol.50
, pp. 6203-6207
-
-
Vassal, G.1
Deroussent, A.2
Hartmann, O.3
-
30
-
-
0024345093
-
Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation
-
Grochow L.B., Jones R.J., Brundrett R.B., et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25 (1989) 55-61
-
(1989)
Cancer Chemother Pharmacol
, vol.25
, pp. 55-61
-
-
Grochow, L.B.1
Jones, R.J.2
Brundrett, R.B.3
-
31
-
-
38149015428
-
High busulfan exposure is associated with worse outcomes in a daily IV busulfan and fludarabine allogeneic transplant regimen
-
Geddes M., Kangarloo S.B., Naveed F., et al. High busulfan exposure is associated with worse outcomes in a daily IV busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 14 (2008) 220-228
-
(2008)
Biol Blood Marrow Transplant
, vol.14
, pp. 220-228
-
-
Geddes, M.1
Kangarloo, S.B.2
Naveed, F.3
-
32
-
-
34648843006
-
Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation
-
Elmaagacli A.H., Koldehoff M., Steckel N.K., Trenschel R., Ottinger H., and Beelen D.W. Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation. Bone Marrow Transplant 40 (2007) 659-664
-
(2007)
Bone Marrow Transplant
, vol.40
, pp. 659-664
-
-
Elmaagacli, A.H.1
Koldehoff, M.2
Steckel, N.K.3
Trenschel, R.4
Ottinger, H.5
Beelen, D.W.6
-
33
-
-
47249084149
-
-
Russell JA, Kangarloo, SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des. (In press).
-
Russell JA, Kangarloo, SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des. (In press).
-
-
-
-
34
-
-
0025243778
-
Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens
-
Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 76 (1990) 1867-1871
-
(1990)
Blood
, vol.76
, pp. 1867-1871
-
-
Clift, R.A.1
Buckner, C.D.2
Appelbaum, F.R.3
-
35
-
-
0036211191
-
Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation
-
Alyea E., Neuberg D., Mauch P., et al. Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 8 (2002) 139-144
-
(2002)
Biol Blood Marrow Transplant
, vol.8
, pp. 139-144
-
-
Alyea, E.1
Neuberg, D.2
Mauch, P.3
-
36
-
-
47249087640
-
Regimen intensity in acute myelogenous leukaemia: addition of 400cGy total body irradiation to a myeloablative fludarabine/busulfan/Thymoglobulin allogeneic transplant regimen reduces relapse without increasing transplant-related mortality
-
(abstract O400)
-
Russell J., Irish W., Savoie L., et al. Regimen intensity in acute myelogenous leukaemia: addition of 400cGy total body irradiation to a myeloablative fludarabine/busulfan/Thymoglobulin allogeneic transplant regimen reduces relapse without increasing transplant-related mortality. Bone Marrow Transplant 41 (2008) S74 (abstract O400)
-
(2008)
Bone Marrow Transplant
, vol.41
-
-
Russell, J.1
Irish, W.2
Savoie, L.3
-
37
-
-
33750205692
-
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome
-
Alyea E.P., Kim H.T., Ho V., et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 12 (2006) 1047-1055
-
(2006)
Biol Blood Marrow Transplant
, vol.12
, pp. 1047-1055
-
-
Alyea, E.P.1
Kim, H.T.2
Ho, V.3
-
38
-
-
4344564516
-
Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens
-
Banna G.L., Aversa S., Sileni V.C., Favaretto A., Ghiotto C., and Monfardini S. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. Crit Rev Oncol Hematol 51 (2004) 171-189
-
(2004)
Crit Rev Oncol Hematol
, vol.51
, pp. 171-189
-
-
Banna, G.L.1
Aversa, S.2
Sileni, V.C.3
Favaretto, A.4
Ghiotto, C.5
Monfardini, S.6
-
39
-
-
33750081766
-
Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents
-
Barrett A.J., and Savani B.N. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 20 (2006) 1661-1672
-
(2006)
Leukemia
, vol.20
, pp. 1661-1672
-
-
Barrett, A.J.1
Savani, B.N.2
|